Rapport Therapeutics, Inc. (RAPP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$23.72-8.52%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · RAPP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -67.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 116 industry peers
RAPP — debt issuance
Dated 2026-10-30
Entry into a Material Definitive Agreement. Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants On October 28, 2026, Rapport Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters (collectively, the “Equity Offering Underwriters”), related to an underwritten public offering (the “Common Stock…
Why it matters: FDA agreement on the trial plan can clear a key step toward Phase 3. Changes to the plan may add time or work.
Watch forThe Q1 2027 FDA meeting ends with agreement on the design for two Phase 3 trials.
Also watch forThe FDA asks for more data or major changes before the Phase 3 design can move forward.
Why it matters: Cash funds the trials, and the company reported a lower balance in September than in June. A sharp drop could weaken its stated runway.
Worry ifThe next filing reports cash below $350 million, or no longer states runway into the second half of 2029.
Less concerning ifThe next filing reports cash at or above $395 million and repeats runway into the second half of 2029.
Why it matters: Both trials test RAP-219 in focal onset seizures. Slow enrollment could delay the pivotal program and its data.
Supportive ifThe next company update confirms FOCUS 1 and FOCUS 2 are still enrolling. No delay has been reported.
Worry ifThe company reports a pause, slow enrollment, or a delay in either FOCUS trial.
Why it matters: Starting both trials on time would show progress from positive Phase 2 results. A delay would push the next major test further out.
Supportive ifRapport starts two Phase 3 trials for acute bipolar mania by December 31, 2027.
Worry ifEither trial has not started by December 31, 2027, or the company reports a delay.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$232 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $598 loss on $10,000 · 6.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,714 loss on $10,000 · 57.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 2 bipolar study reported safety data for only three weeks. Longer-term results can show if RAP-219 remains safe to take.
Watch forQ4 2026 extension data show no new severe or serious safety events. Most patients remain on treatment.
Also watch forThe data show severe or serious safety events, or many patients stop treatment due to side effects.